AU2003233428B2 - Treatment of lung disorder - Google Patents

Treatment of lung disorder Download PDF

Info

Publication number
AU2003233428B2
AU2003233428B2 AU2003233428A AU2003233428A AU2003233428B2 AU 2003233428 B2 AU2003233428 B2 AU 2003233428B2 AU 2003233428 A AU2003233428 A AU 2003233428A AU 2003233428 A AU2003233428 A AU 2003233428A AU 2003233428 B2 AU2003233428 B2 AU 2003233428B2
Authority
AU
Australia
Prior art keywords
atiii
lung injury
antithrombin iii
subject
lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
AU2003233428A
Other languages
English (en)
Other versions
AU2003233428A1 (en
Inventor
Perenlei Enkhbaatar
David N. Herndon
Kazunori Murakami
Donald S. Prough
Daniel L. Traber
Lillian D. Traber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas Medical Branch at Galveston
Original Assignee
University of Texas Medical Branch at Galveston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas Medical Branch at Galveston filed Critical University of Texas Medical Branch at Galveston
Publication of AU2003233428A1 publication Critical patent/AU2003233428A1/en
Application granted granted Critical
Publication of AU2003233428B2 publication Critical patent/AU2003233428B2/en
Assigned to THE UNIVERSITY OF TEXAS MEDICAL BRANCH reassignment THE UNIVERSITY OF TEXAS MEDICAL BRANCH Request for Assignment Assignors: GTC BIOTHERAPEUTICS, INC
Priority to AU2008243077A priority Critical patent/AU2008243077A1/en
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003233428A 2002-04-01 2003-03-25 Treatment of lung disorder Revoked AU2003233428B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2008243077A AU2008243077A1 (en) 2002-04-01 2008-10-31 Treatment of lung disorder

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36899702P 2002-04-01 2002-04-01
US60/368,997 2002-04-01
PCT/US2003/009053 WO2003084476A2 (en) 2002-04-01 2003-03-25 Treatment of lung disorder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2008243077A Division AU2008243077A1 (en) 2002-04-01 2008-10-31 Treatment of lung disorder

Publications (2)

Publication Number Publication Date
AU2003233428A1 AU2003233428A1 (en) 2003-10-20
AU2003233428B2 true AU2003233428B2 (en) 2008-07-31

Family

ID=29420316

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2003233428A Revoked AU2003233428B2 (en) 2002-04-01 2003-03-25 Treatment of lung disorder
AU2008243077A Withdrawn AU2008243077A1 (en) 2002-04-01 2008-10-31 Treatment of lung disorder
AU2011236070A Ceased AU2011236070A1 (en) 2002-04-01 2011-10-10 Treatment of lung disorder

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2008243077A Withdrawn AU2008243077A1 (en) 2002-04-01 2008-10-31 Treatment of lung disorder
AU2011236070A Ceased AU2011236070A1 (en) 2002-04-01 2011-10-10 Treatment of lung disorder

Country Status (10)

Country Link
US (1) US20090221475A9 (https=)
EP (1) EP1494696A4 (https=)
JP (2) JP2005527570A (https=)
KR (2) KR20100117148A (https=)
CN (1) CN100384469C (https=)
AU (3) AU2003233428B2 (https=)
CA (1) CA2480790A1 (https=)
IL (2) IL164078A0 (https=)
NZ (1) NZ535487A (https=)
WO (1) WO2003084476A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169908A1 (en) * 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
US20050245444A1 (en) * 2004-04-30 2005-11-03 Yann Echelard Method of using recombinant human antithrombin for neurocognitive disorders
US20060121004A1 (en) * 2004-12-07 2006-06-08 Yann Echelard Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
US8753882B2 (en) 2010-10-12 2014-06-17 Vetgel Technologies Methods and compositions for treating respiratory conditions using platelet enriched plasma
KR20140093603A (ko) 2010-12-30 2014-07-28 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 병원체 불활성화제로서의 글리콜
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
EP3594231A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
MX384222B (es) 2013-07-05 2025-03-14 Lab Francais Du Fractionnement Matriz de cromatografia de afinidad.
US11491480B2 (en) 2014-06-13 2022-11-08 Children's Medical Center Corporation Products and methods to isolate mitochondria
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
SI4272834T1 (sl) 2016-01-15 2026-03-31 Beth Israel Deaconess Medical Center, Inc. Terapevtska uporaba mitohondrijev in kombiniranih mitohondrijskih sredstev
CN113905724A (zh) * 2019-04-15 2022-01-07 儿童医学中心公司 包含线粒体的雾化组合物及其使用方法
US20240050525A1 (en) * 2021-02-17 2024-02-15 University Of Rochester Methods of treating, diagnosing and predicting prognosis of sepsis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124257A (en) * 1997-08-28 2000-09-26 Lezdey; John Method of treatment

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08782B2 (ja) * 1986-11-22 1996-01-10 株式会社ミドリ十字 抗炎症剤
DE4117078A1 (de) * 1991-05-25 1992-11-26 Boehringer Ingelheim Kg Verfahren zur herstellung therapeutisch anwendbarer aerosole
JPH06256213A (ja) * 1993-03-03 1994-09-13 Green Cross Corp:The ヒト由来アンチトロンビン−ｉｉｉの医薬用途
US6127347A (en) * 1994-01-12 2000-10-03 Univ Michigan Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
US6355626B1 (en) * 1994-05-13 2002-03-12 The Trustees Of The University Of Pennsylvania Antithrombin agents in treatment of asthma
US5843705A (en) * 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US6562781B1 (en) * 1995-11-30 2003-05-13 Hamilton Civic Hospitals Research Development Inc. Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
US7045585B2 (en) * 1995-11-30 2006-05-16 Hamilton Civic Hospital Research Development Inc. Methods of coating a device using anti-thrombin heparin
JPH09176040A (ja) * 1995-12-27 1997-07-08 Green Cross Corp:The ヘパリンコファクターｉｉの医薬用途
US6063593A (en) * 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein
US6838428B2 (en) * 1998-10-20 2005-01-04 Children's Hospital Medical Center Surfactant protein D for the prevention and diagnosis of pulmonary emphysema
WO2000023569A1 (en) * 1998-10-20 2000-04-27 Children's Hospital Medical Center Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
DE10045047A1 (de) * 2000-09-12 2002-03-21 Beate Kehrel Arzneimittel enthaltend aktiviertes Antithrombin III
AU2002224408B2 (en) * 2000-10-18 2007-08-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
US20050169908A1 (en) * 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124257A (en) * 1997-08-28 2000-09-26 Lezdey; John Method of treatment

Also Published As

Publication number Publication date
JP2011225625A (ja) 2011-11-10
KR20100117148A (ko) 2010-11-02
CN1774258A (zh) 2006-05-17
KR20040105838A (ko) 2004-12-16
WO2003084476A2 (en) 2003-10-16
EP1494696A2 (en) 2005-01-12
NZ535487A (en) 2008-12-24
AU2011236070A1 (en) 2011-11-03
CA2480790A1 (en) 2003-10-16
AU2003233428A1 (en) 2003-10-20
WO2003084476A3 (en) 2004-04-22
IL164078A (en) 2011-02-28
CN100384469C (zh) 2008-04-30
IL164078A0 (en) 2005-12-18
AU2008243077A1 (en) 2008-11-27
US20090221475A9 (en) 2009-09-03
JP2005527570A (ja) 2005-09-15
EP1494696A4 (en) 2006-01-25
US20040192595A1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
AU2011236070A1 (en) Treatment of lung disorder
RU2433841C2 (ru) Доставка в легкие альфа-1-ингибитора протеиназ
EP0502054B1 (en) An aerosol preparation of glutathione and a method for augmenting glutathione level in lungs
JPH03501852A (ja) エアゾール化したポリエンを用いる肺の真菌感染の予防及び治療方法
JP2017505348A (ja) 肺疾患治療のための肥満細胞安定剤
JP2015232026A (ja) 人工呼吸器関連肺炎（ｖａｐ）及び人工呼吸器関連気管（ｖａｔ）気管支炎の治療のためのアミカシンとホスホマイシンの組み合わせの製剤並びに方法及びシステム
KR20140108516A (ko) 폐 악화의 발현 또는 진행을 지연시키기 위한 알파1-프로테이나제 억제제
US20200268656A1 (en) Nebulized Ethanol for Internal Disinfecting and Improvement
EP4232073B1 (en) New dosage regimen for inhaled vasoactive intestinal polypeptide
EP1725244B1 (en) Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
KR101924162B1 (ko) 기도의 염증 및 이상성 점액섬모 전달의 치료법으로서의 에어로졸화 댑손
US20220323489A1 (en) Hypochlorous acid solutions for the treatment of drug resistant pneumonia and tuberculosis
RU2737799C1 (ru) Ингаляционный гексапептид для лечения респираторных заболеваний, связанных с интерлейкином-6
KR20100093037A (ko) 폐질환의 건강 관련 삶의 질 부족을 치료하기 위한 흡입용 아즈트레오남 라이신
HK1087930A (en) Treatment of lung disorder
TW201016215A (en) Compositions and uses of antiviral active pharmaceutical agents
US20220064328A1 (en) Formulation of nanoantibody based drugs and a method for treating thrombotic thrombocytopenic purpura by inhalation
Challoner Aerosol delivery of antibiotics
Bauer et al. Special Applications of Aerosol Therapy

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: THE UNIVERSITY OF TEXAS MEDICAL BRANCH

Free format text: FORMER APPLICANT(S): GTC BIOTHERAPEUTICS, INC

FGA Letters patent sealed or granted (standard patent)
MAK Offer to surrender letters patent
MAK Offer to surrender letters patent